---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-312391"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-07-22T20:05:19+00:00"
generated_at: "2026-07-22T20:06:07.446741+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tempest partners with Senlang to develop TPST-4003 in vivo CAR-T; IIT in China expected Q4 2026

## Summary
- Collaboration with Hebei Senlang Biotechnology for TPST-4003, a CD7-targeted in vivo CAR-T candidate.
- First-in-human IIT in ~10 patients with myasthenia gravis or multiple sclerosis; first dosing Q4 2026.
- Development fee range $1.5M-$2.0M per product; Senlang gets exclusive option for China rights.
- Initial safety and PD data expected first half 2027.
- Tempest retains all IP; Senlang will conduct trial in China.

## SEC filing metadata
- accession: 0001193125-26-312391
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-07-22T20:05:19+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526312391/0001193125-26-312391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526312391/d107304d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-312391
- JSON: https://secwatch.observer/filing/0001193125-26-312391.json
- Plain text: https://secwatch.observer/filing/0001193125-26-312391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.